Ireland Strategic Investment Fund has led a $200m series C round for Wuxi NextCode after the latter’s acquisition of ISIF and GV-backed Genomics Medicine Ireland.

Wuxi NextCode, a US-based genomics services provider backed by pharmaceutical firm Amgen, closed a $200m series C round yesterday led by Irish sovereign wealth fund Ireland Strategic Investment Fund (ISIF). ISIF committed $70m to the round and was joined by Singaporean government-owned investment firm Temasek, as well as Yunfeng Capital and Sequoia Capital. Founded as…

The rest of this content is only accessible to Global Corporate Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.